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Accepted 7 March 2012AbstractObjective: To report the natural history and prognosis of the uncommon SertolieLeydig cell tumor (SLCT) of the ovary.
Materials and Methods: A 20-year retrospective review was conducted by the Taiwanese Gynecologic Oncology Group (TGOG), including nine
tertiary medical centers from different regions in Taiwan. The medical records for 40 cases of ovarian SLCT were collected. Pathology reviews
were carried out by a panel of expert pathologists.
Results: After pathological review, 17 patients were subsequently excluded because the pathology slides were unavailable in five cases, and
discrepant results from the initial diagnosis were found in 12 cases (34%). For the remaining 23 patients, the median age was 41 years. The most
common symptom was irregular vaginal bleeding followed by an abdominal mass or amenorrhea. Most of the tumors were unilateral and
confined to the right ovary, with an average size of 8.2 cm. Preoperative serum markers were available for 12 patients and were elevated for three
patients. All patients underwent primary surgery. Six patients accepted adjuvant chemotherapy, and bleomycin, etoposide, and cisplatin were
used in four of them. Clinical follow-up information was available in 21 patients with a median of 19 months. Eighty-two percent of patients
were alive and free of disease up to the date of the last follow-up. Two patients died of the disease.
Conclusion: This study demonstrates the extreme rarity of ovarian SLCT in Taiwan. Histological discordance between the diagnosis and central
review proves the need for expertise review before treatment. For an improved understanding of the biological behavior and treatment strategy
for this unique tumor, international collaboration is imperative.
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Table 1
Patient characteristics (n ¼ 23).
Characteristics n (%) p*
Age (y)
Median 41
Range 16e75
Major symptom
Pain 1 4
Abdominal distention 2 9
Palpable mass 4 17
Irregular vaginal bleeding 10 44
Acne 1 4
Deepening voice 1 4
Amenorrhea 4 17
FIGO stage
I 78
IA 16
IC 2
II 0 0
III 0 0
IV 1 4
Not applicable 4 18
Tumor size (cm)
Mean 8.2
Range 2e22
Laterality
Left 5 22
Right 14 61
Not applicable 4 17
Tumor differentiation
Well 3 13 0.04*
Intermediate 15 65
Poor 5 22
*p value of Fisher’s exact test of overall survival for combined well and in-
termediate differentiation versus poor differentiation.
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Sex cord-stromal tumors account for approximately 7% of
all malignant ovarian neoplasms, and SertolieLeydig cell tu-
mors (SLCTs) represent <0.5% of all ovarian tumors [1].
They are categorized as tumors of low malignant potential, or
low-grade malignancies, with indolent growth patterns. SLCT
occurs most frequently in the second and third decades of life
and typically produces androgens; clinical virilization is noted
in 40% of patients. The androgenic symptoms include oligo-
menorrhea followed by amenorrhea, breast atrophy, acne,
hirsutism, clitoromegaly, a deepening voice, and receding
hairline.
Surgical resection is considered the cornerstone of treat-
ment, and the disease is often diagnosed by pathology fol-
lowing surgery. The disease stage, histologic differentiation,
mitotic index, presence of heterologous elements, and tumor
rupture have all been reported to predict recurrence [2].
However, the role of the standard staging procedure including
lymphadenectomy [3], choice of optimal adjuvant therapy [4],
and efficient treatment in relapse remain perplexing due to the
extreme rarity of this tumor. Here we report the natural history
and prognosis of this uncommon ovarian tumor obtained from
a Taiwanese Gynecologic Oncology Group (TGOG) study.
Materials and methods
A retrospective multi-institutional review of patients with
ovarian SLCT was conducted by the TGOG, including nine
tertiary medical centers from different regions in Taiwan. We
collected the data from 40 cases with ovarian SLCTs diag-
nosed between January 1989 and December 2009. The med-
ical records were reviewed and the clinical manifestations,
demographic and pathological features, treatment strategies,
and outcomes were documented. The hematoxylin and eosin
(H&E) stained slides of the patients were reviewed by a panel
of senior gynecologic pathologists, S.M. Jung (Chang Gung
Memorial Hospital, Taoyuan), C.R. Lai (Taipei Veteran Gen-
eral Hospital, Taipei), M.C. Lin (National Taiwan University
Hospital, Taipei), and T.Y. Wang (Mackay Memorial Hospital,
Taipei). The pathologic diagnostic criteria were based on the
WHO classification [5]. Every slide was reviewed by four
pathologists to reach diagnostic consensus. Slides with dis-
crepancies between the pathologists were then reviewed by
another pathologist for a majority decision. The clinical and
pathological data were then analyzed. Fisher’s exact test for
analysis of the survival and prognostic factors was used. The
retrospective multicenter study was approved by the Institu-
tional Review Boards of the attendant hospitals. Informed
consent was obtained following Taiwanese regulations.
Results
The chart recording system of nine tertiary medical centers
were searched for eligible cases, and 40 patients were found
with SLCT diagnosed between January 1989 and December
2009. Five patients we subsequently excluded because theirtissue slides were not available for pathologic review. There
were discrepancies between the initial histological results and
our subsequent results in 12 (34%) of the remaining 35
patients. The expert pathologists revised the diagnosis to
endometrioid adenocarcinoma (n ¼ 1), poorly differentiated
carcinoma (n ¼ 1), carcinosarcoma (n ¼ 1), and granulosa cell
tumors [granulosa cell tumor (GCT), n ¼ 9]. Finally, total
concordance between the initial diagnosis and the panel
review was achieved in 23 patients (66%). The median age at
diagnosis for these 23 patients was 41 years (range, 16e75
years). More than 70% of the patients were aged <50 years
old at the time of diagnosis. As shown in Table 1, the most
common symptom was irregular vaginal bleeding (44%),
followed by an abdominal palpable mass (17%) or amenorrhea
(17%). All of the patients were diagnosed after surgery, and
most of the tumors were unilateral and confined to the ovary.
The average size of the tumors was 8.2 cm (range, 2e22 cm)
with 60% involving the right ovary. Some of the serum tumor
markers were checked preoperatively, such as cancer antigen-
125 (CA-125), carcinoembryonic antigen, a-fetoprotein(AFP),
inhibin, b-human chorionic gonadotropin, and testosterone in
12 patients, and elevated levels of CA-125, testosterone, and
AFP in three patients. The serum inhibin level assay was not
available in most of the nine tertiary hospitals.
Table 2
Treatment modalities and prognosis.
Items n (%)
Operative methods
Ovarian biopsy 1 4
Unilateral oophorectomy 6 26
TAH þ BSO 5 22
Fertility-sparing staging operation 5 22
Staging operation 6 26
Adjuvant treatment
No 18 78
Yes 5 22
Radiation therapy 1a
Chemotherapy 5
BEP 3
Other regimen 1
Unknown 1
Prognosis
Alive without disease 19 82
Died of disease 2 9
Loss of follow-up 2 9
BEP ¼ bleomycin, etoposide, and cisplatin; BSO ¼ bilateral salpingo-
oopherectomy; TAH ¼ total abdominal hysterectomy.
a Palliative radiation therapy for pathologic fracture at recurrence.
68 C.-S. Weng et al. / Taiwanese Journal of Obstetrics & Gynecology 52 (2013) 66e70All patients underwent primary surgery (Table 2); 11 (48%)
had a complete staging operation, six had optimal debulking
surgery, and five had a fertility-sparing staging operation. The
median number of lymph nodes removed was 18 (range,
0e36), and none of them showed metastasis. Six patients (four
with stage IA disease and poorly differentiated tumors, one
with stage IC, and one with stage IV disease) accepted adju-
vant chemotherapy. Four patients received bleomycin, etopo-
side, and cisplatin (BEP). Follow-up information was available
for 21 patients, with a median of 19 months (range, 4e156
months). Nineteen patients (82%) were free of disease up to
the date of the last follow-up. Two patients died of the disease
(DOD) and their clinical features are shown in Table 3. The
first DOD case underwent a unilateral salpingo-oophorectomy
for a poorly differentiated tumor and four cycles of adjuvant
chemotherapy with BEP. The patient suffered from pelvic
recurrence 2 years after the primary treatment and then un-
derwent a second debulking surgery and salvage chemo-
therapy with BEP. She died 30 months after the initial
diagnosis. The second DOD patient, with bony metastasis
stage IV disease, underwent optimal debulking surgery and
five courses of chemotherapy with BEP. The chemotherapy
was switched to weekly paclitaxel due to poor response, andTable 3
Clinical features of the 2 patients who died of SertolieLeydig cell tumor (SLCT)
Patient
(age, y)
Symptoms Tumor
size
Stage Differentiation Surgery
1 (21) Abdominal
palpable mass
22 cm IA Poor Unilateral oo
2 (53) Abdominal
palpable mass,
back pain
12 cm IV Poor Total hystere
bilateral salp
omentectomy
lymphadenecshe died 13 months after her initial diagnosis. The two DOD
cases were in the category of poorly differentiated tumors, and
none of the patients with well differentiated or moderately
differentiated tumors died of the disease. Using Fisher’s exact
test for analysis, poor differentiation was found to be a statis-
tically significant poor prognostic factor as compared to the
well and intermediate differentiations ( p ¼ 0.04).Discussion
SLCT is a rare histologic type of ovarian cancer. Studies on
the topic have always enrolled too few cases to provide clinical
relevance and treatment modalities, as is the case with the 23
women included in this retrospective multi-center TGOG study.
SLCT comprised diverse pathologic characteristics that can
complicate the efforts of the pathologist and gynecologist to
make correct diagnoses, including primary and metastatic
ovarian cancers (Table 3) [4,5]. In a study for rare malignant
ovarian tumors conducted by the GINECO [Group d’Inves-
tigateurs Nationaux pour l’Etude des Cancers Ovariens
(France)] group, discrepancies between the initial diagnosis and
central review occurred in 37% of their cases [6]. Similarly, the
diagnosis was changed after pathologic review in 12 (34%) of
our cases, with the majority of them shifting to GCTs. Among
these 12 patients with inconsistent diagnoses, seven were ini-
tially designated with poorly differentiated SLCTs. Our results
remind pathologists to use more caution in reaching the correct
diagnosis to enable proper subsequent treatment planning.
Due to the diagnosis controversy, a new category system
was developed by the World Health Organization [7]. In
addition to the new consensus on the pathologic features of
H&E staining, immunohistochemical (IHC) studies had
proven useful in differentiating tumors. Negative staining for
epithelial membrane antigen and positive staining for inhibin
and calretinin were the most remarkable for SLCT [8]. CD56,
FOXL2, DICER-1, WT1, and CD10 were also reported as
helpful for differentiating tumors [9e13]. A combination
panel of IHC stains and H&E stains is believed to be the best
method for correctly diagnosing SLCTs.
The average age of the women in our study was 41 years,
much older than the 25 years previously reported [2,14,15].
Thirty-five percent (8/23) of our patients were younger than 30
years. In the largest case study of ovarian SLCT published by
Young and Scully [2], the average age of the patients with
well-differentiated tumors was 10 years higher than the overallof the ovary.
Recurrence
site
Adjuvant therapy after
recurrence
phorectomy Peritoneal
cavity
Chemotherapy with bleomycin,
etoposide, cisplatin
ctomy,
ingo-oophorectomy,
, pelvic/para-aortic
tomy
Bone
metastasis
initially
Chemotherapy with bleomycin,
etoposide, and cisplatin, then changed
to weekly paclitaxel; radiation for
bony metastasis
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well-differentiated tumors was 50 years, and for patients with
tumors of intermediate and poor differentiation the ages were
40.7 years and 31.8 years, respectively.
Ovarian SLCTs may secrete androgens, but only 25% of
our study patients presented with androgenic symptoms
because clinical data for this item was lacking, which might be
due to differences in clinical practice at the various medical
centers. Elevation of serum CA-125 did not help diagnose or
detect SLCT because it occurred in only one out of seven
patients. Most of the SLCTs were confined to a unilateral
ovary, especially the right-side ovary as shown in our study
(61%). Bilateral involvement was as low as 1.5% in Young and
Scully’s report and there were none in our patients. For most
of the previously reported cases with bilateral tumors [16e19],
Young and Scully suggested the possibility of other diagnoses,
such as Krukenberg tumors or luteinized thecomas. Therefore,
the diagnosis of ovarian SLCT should be made cautiously for
those women with high-stage and bilateral occurrences.
Likewise, in our discordant diagnosis group, in spite of the
nine GCTs, which are also more likely to be present in early
stage disease, the carcinosarcoma and poorly differentiated
tumors had bilateral involvement and were present with
advanced disease.
Surgical resection is the primary treatment for ovarian
SLCT. Since most of the patients were diagnosed at repro-
ductive ages with early stage disease, fertility-sparing surgery
was considered appropriate due to the prospect of good out-
comes. In recent published studies, it has been suggested that
the routine lymphadenectomy might be unnecessary for
sex-cord stromal tumors [20,21]. Eleven of our patients had
nodal evaluations and all of them were negative for metastasis.
The indications and regimen for postoperative adjuvant
chemotherapy could not be determined due to the limited
number of cases in our study, except that tumors with poor
differentiation were found to be related to worse outcome.
Aggressive treatment and intensive surveillance may be nee-
ded for poorly differentiated tumors. Furthermore, studies
have shown that a high disease stage, poor tumor differentia-
tion, high mitotic index, presence of heterologous compo-
nents, and tumor rupture were poor prognostic factors that
required adjuvant chemotherapy [2,14,15]. As for chemo-
therapy, platinum-based chemotherapy had been widely used
for sex cord-stromal tumors [22]. In a prospective clinical trial
for sex cord-stromal tumors where BEP was used, the overall
response rate was high, but the relapse rate was >50% [23].
Six of our patients underwent chemotherapy for poorly dif-
ferentiated tumors or extraovarian spread, and four of them
had the BEP regimen. One case was refractory to BEP and
another developed recurrent disease 2 years later. A large scale
study is needed to define the best regimen.
Our study of 23 patients with ovarian SLCT over a 20-year
period demonstrates the rarity of this type of ovarian cancer in
Taiwan. The high discrepancy rate between initial diagnosis
and central review suggests the necessity of pathological
attention, using both H&E and IHC stains for correct diag-
nosis. Conservative surgery is suggested for women in earlystages and in need of fertility, with unchanged prognoses.
Adjuvant chemotherapy may be considered when tumors with
poor differentiation or advanced stage are encountered,
although the best regimen could not be determined in our
study. International cooperation is warranted to improve our
understanding of the biological behavior and treatment strat-
egies for this unique tumor.Acknowledgments
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